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Abstract
Background: Ankylosing spondylitis (AS) is an immune-mediated arthritis particularly targeting the spine and pelvis
and is characterised by inflammation, osteoproliferation and frequently ankylosis. Current treatments that predominately
target inflammatory pathways have disappointing efficacy in slowing disease progression. Thus, a better understanding
of the causal association and pathological progression from inflammation to bone formation, particularly whether
inflammation directly initiates osteoproliferation, is required.
Methods: The proteoglycan-induced spondylitis (PGISp) mouse model of AS was used to histopathologically map the
progressive axial disease events, assess molecular changes during disease progression and define disease progression
using unbiased clustering of semi-quantitative histology. PGISp mice were followed over a 24-week time course. Spinal
disease was assessed using a novel semi-quantitative histological scoring system that independently evaluated the
breadth of pathological features associated with PGISp axial disease, including inflammation, joint destruction and
excessive tissue formation (osteoproliferation). Matrix components were identified using immunohistochemistry.
Results: Disease initiated with inflammation at the periphery of the intervertebral disc (IVD) adjacent to the longitudinal
ligament, reminiscent of enthesitis, and was associated with upregulated tumor necrosis factor and metalloproteinases.
After a lag phase, established inflammation was temporospatially associated with destruction of IVDs, cartilage and bone.
At later time points, advanced disease was characterised by substantially reduced inflammation, excessive tissue
formation and ectopic chondrocyte expansion. These distinct features differentiated affected mice into early,
intermediate and advanced disease stages. Excessive tissue formation was observed in vertebral joints only if the
IVD was destroyed as a consequence of the early inflammation. Ectopic excessive tissue was predominantly
chondroidal with chondrocyte-like cells embedded within collagen type II- and X-rich matrix. This corresponded
with upregulation of mRNA for cartilage markers Col2a1, sox9 and Comp. Osteophytes, though infrequent, were
more prevalent in later disease.
Conclusions: The inflammation-driven IVD destruction was shown to be a prerequisite for axial disease progression to
osteoproliferation in the PGISp mouse. Osteoproliferation led to vertebral body deformity and fusion but was never seen
concurrent with persistent inflammation, suggesting a sequential process. The findings support that early intervention with
anti-inflammatory therapies will be needed to limit destructive processes and consequently prevent progression of AS.
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Background
Ankylosing spondylitis (AS) is a chronic inflammatory
arthritis predominantly affecting the axial skeleton, par-
ticularly the spine and pelvis. The disease is characterised
by inflammation at the entheses, which is followed by un-
controlled osteoproliferation that often leads to fusion
(ankylosis) of affected joints. There is ongoing debate re-
garding whether inflammation is the direct trigger of the
osteoproliferation seen in AS. Whilst there is evidence
that the anti-inflammatory treatments of non-steroidal
anti-inflammatory drugs (NSAIDs) and tumour necrosis
factor (TNF)-inhibitor biologic therapies can slow osteo-
proliferative disease, the outcome is variable and the effect
is at best partial with ankylosis still progressing. Ankylosis
in patients with AS results from the development and fu-
sion of syndesmophytes, defined as bony bridges growing
at the vertebral corners. Multiple mechanisms of bone for-
mation have been proposed to underlie the osteoprolifera-
tion in AS, including intramembranous, endochondral
and chondroidal ossification [1, 2]. The causative patho-
logical mechanism that initiate and perpetuate the exces-
sive bone formation and subsequently ankylosis remain
unknown.
In patients with AS, longitudinal magnetic resonance
imaging (MRI) and radiographic imaging can be used to
follow disease progression, but the resolution and sensi-
tivity of these imaging modalities are insufficient to show
correlations of specific pathological processes at a de-
tailed anatomical level. Collection of serial biopsies from
spinal lesions of patients with AS would substantially aid
elucidation of mechanistic changes underlying the in-
flammatory response and the mechanism(s) of bone for-
mation. However, this approach is constrained because
of ethical limitations and biopsy collection challenges. A
few studies have been performed on sacroiliac joint biop-
sies from patients undergoing hip replacement and in
zygapophyseal joints from spinal surgeries [2–6]. Such
studies, though informative, are limited by sample size
and anatomical location, coupled with being predomin-
antly obtained from late-stage disease patients in whom
the inflammation-osteoproliferative transition has already
occurred. Disease-relevant animal models thus present
the only viable approach to elucidate mechanisms under-
lying disease progression in the axial skeleton. Time
course studies in spinal samples from animal models
present a powerful approach to biologically map the full
progression of AS, particularly to investigate the mechan-
istic link between inflammation and osteoproliferation.
We aimed to delineate the disease progression and
causal association between inflammation, destruction and
osteoproliferation in AS by undertaking a comprehensive
time course study in the proteoglycan (PG)-induced
spondylitis (PGISp) mouse model. The PGISp mouse
model was chosen for its recapitulation of AS clinical
features, including development of both inflammation
and osteoproliferation in the spine in response to an
immune stimulus [7, 8]. These previous studies in the
PGISp model demonstrated intervertebral disc (IVD)
destabilization, cartilage damage, chondrophyte/osteo-
phyte formation and their subsequent fusion. However,
these studies were qualitative and the inter-dependence
between these features was not assessed.
We performed a 6-month time course in PGISp mice
spanning from the onset to advanced disease with regu-
lar sampling occurring throughout disease progression.
We developed a novel histological scoring system that
measured the full breadth of disease features. Unbiased
computational modelling of these scores allowed us to
determine the key features differentiating different dis-
ease stages and predict associations. We used histology,
immunohistochemistry, and gene expression data to pre-
cisely characterise the timing and morphology of patho-
logical events within affected joints.
Methods
Mouse model, immunization and collection
The PGISp model was established by treating 3-month-
old female IL-4−/− BALB/c mice with 2 mg of human
cartilage extract (PG) together with 2 mg of dimethyl
dioctadecyl ammoniumbromide (DDA) (Sigma-Aldrich, St.
Louis, MO, USA) as described previously [8]. IL-4−/−mice
were used because of the higher disease incidence and
severity over wild-type BALB/c mice [9]. PG was adminis-
tered via intraperitoneal injections at week 0, 3 and 6 of the
study. Age-matched naïve female IL-4−/− BALB/c mice
were used as controls.
Spine samples, including thoracic and lumbar spine,
from 12 to 17 mice were collected 6, 8, 10, 12, 16 and
24 weeks after the first PG injection. All experiments
were approved by the University of Queensland animal
ethics committee.
Histology
Spine samples from 5 to 10 mice per group were fixed
in 4 % paraformaldehyde (Sigma-Aldrich) for 48–72 hours
followed by decalcification in 14 % ethylenediaminetet-
raacetic acid disodium salt dihydrate (EDTA) (Sigma-
Aldrich) for 3–4 weeks. Embedded spine samples were
cut into 5-μm serial sections along the sagittal plane
using a standard rotary microtome. Sections were deparaf-
finised with xylene and graded ethanol, rehydrated in tris-
buffered saline (TBS) (50 mM Tris, 150 mM NaCl, pH =
7.4), stained with Mayer’s haematoxylin and eosin (H&E)
or toluidine blue (0.01 % toluidine blue O (Sigma-Aldrich)
in 0.1 % sodium chloride solution, pH = 2.0) and
mounted.
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Semi-quantitative histological scoring
Histological scoring criteria outlined in Table 1 were de-
veloped to capture the broad range of inflammatory, cata-
bolic and anabolic changes that occur within the vertebral
joints of the spine in this AS model. Scoring was per-
formed on one H&E and one toluidine blue stained sec-
tion from each sample. Only samples with correct sagittal
orientation and at least six IVDs in the section plane were
included in the analysis. On average, nine vertebral joints
were scored in each mouse. Anterior and posterior sides
of each joint were scored separately and then averaged to
generate the final score for any given joint. Joints with a
score above zero within any of the criteria categories were
defined as affected joints, and mice that had at least one
affected IVD were defined as affected mice. PGISp mice
with normal spine morphology and no evidence of disease
were excluded from further spinal disease incidence and
progression analysis. The disease progression was mea-
sured by averaging scores of all vertebral joints.
Immunohistochemistry
Sagittal sections (4-μm) were rehydrated and subjected
to different antigen retrieval processes depending on the
primary antibody. For type I and II collagen, spine sec-
tions were digested in pre-warmed 25 % trypsin (Biocare
Medical, Concord, NSW, Australia) for 10 min at room
temperature (RT). For type X collagen, sections were
incubated in 0.1 U/ml chondroitinase ABC (Sigma-
Aldrich) in tris-acetate buffer (0.1 M Tris, 30 mM
Acetate buffer, 10 mM EDTA, pH 6.5) for 2 hours at
37 °C. No antigen retrieval was performed for osterix
antibody. All sections were incubated in 3 % H2O2 for
30 min at RT and blocked in Sniper Blocking Reagent
(Biocare Medical) for 10 min followed by 10 % foetal
bovine serum for 1 hour at RT. For type I or II colla-
gen and osterix staining, sections were incubated with
rabbit anti-type I or II collagen or osterix antibodies
or equivalent concentration of normal rabbit IgG for
1 hour at RT. For type X collagen staining, sections
were incubated with rabbit anti-type X collagen anti-
serum or equivalent concentration of rabbit serum
overnight at 4 °C. After washing in TBS, sections were
incubated in MACH1 HRP polymer reagent (Biocare
Medical) for 30 min and detected by using diamino-
benzidine (DAB) chromogen (Biocare Medical). Sec-
tions were counterstained in acidified haematoxylin
Table 1 Histological score criteria
Category Score Criteria
Inflammation 0 Normal
1 Minor infiltration of inflammatory cells at periphery of the joint
2 Moderate infiltration – inflammatory pannus < 50 % joint area
3 Marked infiltration – inflammatory pannus > 50 % joint area
Intervertebral disc destruction 0 Normal
1 Less than 50 % disc destruction
2 More than 50 % disc destruction
3 Total disc destruction/only necrotic disc left
Cartilage damage 0 Normal
1 Some loss of articular cartilage or growth plate cartilage or both
2 Severe loss of articular cartilage and some growth plate cartilage damage
3 Severe loss of articular cartilage and severe growth plate cartilage damage
Bone erosion 0 Normal
1 One or a few small areas of resorption in original vertebral bone.
2 Numerous areas of obvious focal resorption in original vertebral bone or
several areas of severe destruction.
Excess tissue formation (excluding inflammatory infiltrate) 0 Normal
1 Mesenchymal cell invasion or expansion or both
2 Moderate fibrocartilage formation (<50 % of the original disc area)
3 Extensive fibrocartilage formation (>50 % of the original disc area)
Ectopic chondrocytes/chondrophyte 0 Normal
1 Single small area
2 Single large area
3 Multiple areas
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(Sigma-Aldrich). Reagent details are listed in Additional
file 1: Table S1.
RNA extraction and quantitative real-time polymerase
chain reaction
Spine samples from five to eight PGISp or from five to
seven age-matched naïve female mice at each time point
were flash-frozen in liquid nitrogen and stored at −80 °C.
Spine samples were homogenized separately in Trizol
(Life Technologies, Mulgrave, Victoria, Australia), and
RNA extracted as described previously [8]. Synthesis of
cDNA was conducted by using a Tetro cDNA synthesis
kit (Bioline, Alexandria, NSW, Australia) in accord-
ance with the instructions of the manufacturer. Gene
expression was measured by SYBR Green-based quan-
titative real-time reverse transcription polymerase chain
reaction (qPCR) using the Sensimix SYBR kit and run
on a ViiA7 Real-Time PCR System (Life Technologies).
Primer sequences are listed in Additional file 1: Table S2.
PCR conditions were 10 min at 95 °C followed by
50 cycles of 15 sec at 95 °C and 45 sec at 60 °C. The
expression of individual genes was normalized to β-actin
and gene expression quantified by using the ΔCT
equation.
Statistics
Data was analysed by Mann-Whitney or Kruskal-Wallis
tests analysis by using PRISM 6 (GraphPad Software, La
Jolla, CA, USA). P values of less than 0.05 were consid-
ered significant. Unsupervised analysis was conducted by
using the hclust function in R. Histological scores of af-
fected IVD of affected mice were averaged and com-
puted by using hierarchical cluster analysis with Ward’s
method.
Results
PGISp axial joint histopathology progresses from
inflammation to osteoproliferation
To characterise axial disease progression in PGISp mice,
H&E stained sections from spines collected across a
24-week disease time course were semi-quantitatively
scored in accordance with the criteria outlined in Table 1.
These criteria scored inflammation, vertebral disc destruc-
tion, bone erosion, excess tissue formation (mesenchymal
tissue expansion or fibrocartilage formation) and ectopic
chondrocyte/chondrophyte formation in the vertebral
joints. Histological scoring of these major disease features
was used to model axial disease progression in the PGISp
mice. All the vertebral joints and IVD in naïve mice ap-
peared normal throughout the time course and were
treated as a single mouse group for statistical analysis.
The PGISp mice exhibited early disease by 6 weeks
post-PG priming, and 60 % of mice had either one or
two mildly affected vertebral joints. By 8 weeks after the
first PG injection, every PGISp mouse had at least one
affected vertebra, and 50 % of all vertebral joints were af-
fected (Fig. 1a). The majority of joints were only mildly
affected at 8 weeks, but severe inflammation was ob-
served in a small percentage (Fig. 1a). Averaging the in-
flammatory scores of all the vertebral joints in individual
affected PGISp mice and comparing this average inflam-
mation score across the time course showed that inflam-
mation peaked at 12 weeks (Fig. 1b), and 18–19 % of
affected joints were severely inflamed (Fig. 1a). At both
10 and 12 weeks after PG priming, the inflammation
score was significantly elevated (Fig. 1b). There was het-
erogeneity in inflammation severity at any time point
both between and within individual animals, and some
vertebral joints showed no inflammation whereas others
had significant inflammatory infiltrates (Fig. 1b). Average
inflammation severity decreased from 16 weeks after PG
priming, and by 24 weeks the majority of joints had no
or only very minor associated inflammation (Fig. 1a).
When compared with all other histopathological features
scored (Fig. 1c–g), inflammation was the earliest detect-
able axial histopathological feature in the PGISp model
but was a transient disease process (Fig. 1b).
Histopathological features of the disease reflecting de-
struction (Fig. 1c–e) or tissue formation (Fig. 1f and g)
demonstrated a sustained or progressive disease pattern.
Most reached maximal score at 24 weeks after priming
(Fig. 1c–e), much later than was observed for inflamma-
tion scores (Fig. 1b). Initiation of disc destruction (Fig. 1c),
bone erosion (Fig. 1d), cartilage damage (Fig. 1e) and ex-
cessive tissue formation (Fig. 1f) were evident from 8 weeks
after priming. Disc destruction and bone erosion were
significantly increased from week 10 onwards in PGISp
compared with naïve mice (Fig. 1c and d, respectively).
Disc destruction (Fig. 1c) and bone erosion (Fig. 1d)
peaked at the same time as inflammation (Fig. 1b) but
subsequently plateaued, consistent with their being ir-
reparable tissue changes driven by the inflammatory
processes. Excessive tissue (Fig. 1e) and ectopic chon-
drocyte formation (Fig. 1f ) increased steadily from
week 10 through to week 24.
A notable feature was that, in all the mice analysed,
severe inflammation and significant excessive tissue
formation did not occur simultaneously within the
same joint, consistent with these features represent-
ing distinct early and late stages of PGISp progres-
sion, respectively. Another feature of late-stage disease
was cartilage damage, which was not significantly ele-
vated compared with naïve or 6-week mice until
16 weeks after PG priming. This suggests that this de-
structive event is more likely a secondary consequence
of other joint changes initiated by the inflammatory
process, rather than a direct consequence of the
inflammation.
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Inflammation drives tissue damage and disc destruction
in PGISp mice
Detailed histological assessment across the time course
exemplified the heterogeneity of disease progression be-
tween different animals and even between individual
vertebral joints, similar to that reported previously in this
model [7, 8] and in AS [10]. At the 6-week time point, the
earliest detected feature of inflammation was accumula-
tion of inflammatory cells at the periphery of the IVD ad-
jacent to the annulus fibrosus (AF) (Fig. 2a). At 8 weeks
Fig. 1 PGISp mouse model disease progression. a The severity of inflammatory infiltrate is represented by the percentages of different scores at each
time point. Axial disease progression is described by the features of (b) inflammation, (c) disc destruction, (d) bone erosion, (e) cartilage damage, (f)
excessive tissue formation and (g) ectopic chondrocyte formation. Each point represents the average scores of all vertebral joints within each affected
mouse at the particular time points (3–10 mice per time point). The results are shown as mean ± standard deviation and analysed by Kruskal-Wallis test
followed by Dunn’s multiple comparison test. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05 compared with naïve
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after priming, while all mice were affected, within any
given PGISp mouse, both affected (Fig. 2b, joints 2 to 4)
and unaffected (Fig. 2b, joints 1 and 5) vertebral joints
were observed and there was a broad range of inflamma-
tion severity within a single spine (Fig. 2b, joints 2–4). In-
flammatory pannus invading into the disc space was
clearly associated with IVD destruction, resulting in joint
space narrowing (Fig. 2b, space between arrows), and was
often associated with bone erosion (Fig. 2c, arrowhead).
Early hyaline cartilage damage, including eroded surfaces
defined by excavated and empty chondrocyte lacunae, was
confined to areas exposed to inflammatory infiltrate (Fig. 2c,
yellow dash line represented eroded cartilage surface), simi-
lar to previous observation in vertebrae and sacroiliac joints
in PGISp mice [7, 8].
Severe inflammation was characterised by marked infil-
tration of the AF by inflammatory cells, including poly-
morphonuclear cells, vascular structures and increased
density of mixed morphology mesenchymal cells (Fig. 2c
and d). In severely inflamed joints, periosteal expansion
and inflammatory cell invasion frequently extended along
the cortical surface of the vertebral body, possibly following
the spinal ligaments, suggesting an entheseal or periosteal
pathology or both (Fig. 2e, arrows). Overall the histopath-
ology features suggest that the inflammatory process drives
the IVD destruction, focal cartilage damage and focal bone
erosion, particularly at the vertebral corners, all of which
are reported features of AS axial pathology.
TNFα and matrix metalloproteinase-3 (MMP-3) and
MMP-13 have been implicated in AS inflammatory
Fig. 2 Progression of spinal inflammation in PGISp mice. a Representative H&E stain of mild inflammation in an 8-week time point mouse. Inflammatory
cells accumulate at the periphery of the disc (arrow), but the rest of the intervertebral disc appears normal. AF annulus fibrosus, CEP cartilaginous end
plate, GP cartilaginous growth plate, NP nucleus pulposus. Scale bar = 300 μm. b Variable disease penetrance in an 8-week PGISp mouse:
(1) and (5) unaffected intervertebral discs, (2) disc destruction combined with early chondrocyte formation, (3) severe inflammation and
disc destruction, and (4) moderate inflammation with incomplete disc destruction. Scale bar = 2 mm. c Magnification of the boxed area in (b) shows
bone erosion (arrowhead) and cartilage damage. The yellow dashed line indicates the eroded cartilage surface. Scale bar = 60 μm. d
Magnification of the boxed area in (b) demonstrating large numbers of mononuclear cells presenting in the affected joints. Scale bar = 60 μm. e
Inflammation expansion along the longitudinal ligament (arrows). f mRNA expression of Mmp3, Mmp13 and Tnf in whole spine was analysed by qPCR
and normalized to β-actin. Black bars represent naïve and open bars represent PGISp mice. Expression levels are presented as mean ±
standard deviation. ***P< 0.0001, **P < 0.001, *P < 0.01 compared with naïve at the same time point, Mann-Whitney test. MMP matrix metalloproteinase,
TNFα tumour necrosis factor-alpha
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processes and have been correlated with disease activity
[11–13]. Therefore, mRNA expression of these genes in
the whole spine was measured by qPCR (Fig. 2f ). The
basal level of Mmp3 in unaffected mice was very low
across the time course (Fig. 2f, black bars). PG immun-
isation induced a dramatic elevation of Mmp3 at 8 weeks
and expression levels of this transcript remained signifi-
cantly higher in PGISp mice when compared with naive
mice at all later time points (Fig. 2f ). Mmp13 was sig-
nificantly elevated at weeks 12 and 16 in PGISp spines.
Tnf expression was significantly increased in PGISp mice
at 8 and 16 weeks (Fig. 2f ). These data suggest that
the inflammation-driven tissue remodelling molecular
cascades are established by 8–10 weeks post-immunisation
and decrease in parallel with inflammation during the later
disease stages.
Disease-associated anabolic tissue formation
Expansion of mesenchymal cells, predominantly fibroblast-
like (Fig. 3a i and ii, arrowheads) and chondrocyte-like
(Fig. 3a i and ii, arrows), was noted in the bulging residual
AF of affected vertebral joints and extending along the ver-
tebral periosteal surface (Fig. 3a). The chondrocyte-like cell
phenotype included rounded or polygonal morphology
within a dense predominantly basophilic extracellular
matrix (ECM) (Fig. 3a i and ii, arrows). In advanced
Fig. 3 Excessive tissue and ectopic chondrocyte formation are key features of advanced disease. a A 12-week mouse IVD demonstrates both early (i)
and intermediate (ii) stages of excessive tissue formation using H&E stain. Scale bar = 300 μm. Inflammatory infiltrate (yellow arrow) surrounds the
affected joint, while fibroblast-like cells (arrowheads) and chondrocyte-like cells (arrows) are located adjacently to the residual disc (asterisks).
Scale bar = 200 μm in (i) and (ii). CEP cartilaginous end plate. b Excessive tissue at the periphery of the joint is greatly increased in more
advanced disease (arrows). Representative image from a 24-week mouse. Scale bar = 400 μm. c In addition to excess tissue (black arrow),
columnar chondrocytes expand ectopically along the cortical bone between affected joints (yellow arrowheads). Representative image from
a 24-week mouse. Scale bar = 300 μm. d Representative images taken from 24-week mice show an unaffected IVD and affected joints with
excessive or ectopic chondrocyte formation. Cartilaginous tissue (arrows) is positive for toluidine blue (proteoglycan content) and type II
collagen. Type X collagen stains for hypertrophic chondrocytes while type I collagen delineates mature bone. Scale bar = 100 μm. e Spinal
gene expression profiles of cartilage markers Col2a1, Comp and Sox9 were analysed by qPCR reaction and normalized to β-actin. Black bars
represent naïve and open bars represent PGISp mice. Expression levels are presented as mean ± standard deviation. ***P < 0.0001, **P < 0.001, *P < 0.01
compared with naïve at the same time point, Mann-Whitney test. Col2a1 type II collagen, α 1, COMP cartilage oligomeric matrix protein,
Sox9 sex determining region Y- box 9
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disease, ectopic cartilaginous tissue increased as the in-
flammatory cell infiltrate and density of fibroblast-like
mesenchymal cells declined (Fig. 3b, arrows). Ectopic
chondrogenesis/chondrophyte formation occurred only
following disc destruction, and residual necrotic disk
tissue was frequently evident (Fig. 3a, asterisks). Ectopic
cartilage-like tissue containing embedded chondrocytes
in columnar formation parallel to the vertebral perios-
teal cortical surface was also observed in some mice
and was possibly associated with longitudinal ligament
attachment points (Fig. 3c, yellow arrowheads). Inter-
estingly, the cortical bone underlying the columnar
cartilage-like tissues had evidence of erosive damage,
including pitting of the periosteal surface (Fig. 2c). In-
flammation was noted in similar regions of other mice
(Fig. 2e, arrows), as were cells with chondroblast-like
morphology embedded within dense ECM (Figs. 3aii and b).
These features were not observed concomitantly on any
given vertebral body, suggesting that while they occurred at
a similar anatomical location, they were temporally stag-
gered processes, although owing to cross-sectional experi-
mental design, these observations are correlative.
The composition of the ectopic ECM present at sites
of PGISp excess tissue formation was determined by
assessing distribution of different types of collagen by
immunohistochemistry (Fig. 3d). In unaffected vertebral
joints (Fig. 3d, top row), the AF and endplate hyaline
cartilage had high PG content (toluidine blue-positive)
and predominantly contained type II collagen. Type I
collagen was weakly present in AF but was a major com-
ponent of the vertebral bone. In affected joints (Fig. 3d,
middle and bottom row), the majority of the excessive
tissue (Fig. 3d, arrows) had a high PG content and con-
tained both type II and type X collagens, verifying patho-
logic chondroproliferation. Expression of type X collagen
suggested that some chondrocytes were hypertrophic.
Consistent with previous findings, weak collagen type I
staining seen at the periphery of excessive tissue areas,
potentially indicated progression towards formation of
bone [8].
Spinal mRNA expression of cartilage matrix components
and cartilage-forming regulatory proteins fluctuated during
disease progression (Fig. 3e). Expression of cartilage com-
ponents col2a1 and Sox9 was decreased at 8 and 6 weeks
post-priming, respectively. From 10 weeks onwards, as
inflammation peaked and excessive tissue formation in-
creased, cartilage oligomeric matrix protein (Comp) was
significantly elevated. Col2a1 was upregulated at week 12
whereas Sox9 increased at weeks 10 and 24. This trend
suggests cartilaginous matrix expression was increased in
PGISp mice after the peak of inflammation.
Mature osteophyte formation, defined as aberrant bone
formation adjacent to cortical bone (Fig. 4a), was appar-
ent. Osteophytes showed a variable collagen distribu-
tion with different areas containing collagen I-, II- or
X-positive and osterix-positive cells (Fig. 4b). None of
the PGISp mice at weeks 6 and 8 developed osteophytes,
but 28.6 % of mice at week 10 had osteophytes, and the
percentage increased to 71.4 %, 66.7 % and 75 % at weeks
12, 16 and 24, respectively. A noteworthy observation is
that pathological tissue formation was observed only with
vertebral joints that exhibited IVD destruction.
Fig. 4 New bone and osteophyte formation. a Representative image of an osteophyte (arrow) in the affected joint of a 12-week proteoglycan-induced
spondylitis mouse. Scale bar = 300 μm. b Recently formed bone tissue (arrowheads) is characterised by a transition from proteoglycan and type
II collagen-enriched matrix to type X and type I collagen-positive matrix. Osterix-positive osteoblasts are embedded in type I collagen-positive bone
matrix. The dashed line represents the boundary between the original cortical bone and the excessive matrix above, showing a reduction of
cartilaginous matrix, toluidine blue staining and type II collagen accompanied with an increase of type I collagen and osterix-expressing osteoblasts.
Arrowheads indicate cartilage tissue that is strongly positive for type II collagen but weakly for type I collagen. Scale bar = 100 μm.
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Modelling of disease
To unbiasedly model the interdependence of the different
scoring criteria irrespectively of time post-PG priming, we
developed an algorithm to define different disease stages.
This algorithm used an unsupervised clustering approach
based purely on average affected vertebral joint scores
across all the criteria measured. This clustering defined
three disease stages which interestingly corresponded
broadly to the time point post-priming—stage 1: early
(mainly week 6 to 8, Fig. 5a, left box); stage 2: intermediate
(mainly weeks 10 to 12, Fig. 5a, middle box); and stage 3:
advanced (mainly weeks 16–24, Fig. 5a, right box). Stage 3
could also be divided into two subgroups with a very late
cluster consisting of almost entirely 24-week mice. We
further dissected the data to identify the scoring metrics
that best delineated each stage. The scores for inflam-
mation (Fig. 5b), excessive tissue formation (Fig. 5c) and
ectopic chondrocyte formation (Fig. 5d) strongly differen-
tiated between these three groups. The early stage showed
mild to moderate inflammation, low excessive tissue and
low ectopic chondrocyte formation. The intermediate
stage displayed severe inflammation and moderate ex-
cessive tissue and ectopic chondrocyte formation. The
advanced stage showed decreased inflammation but pro-
nounced excess tissue and ectopic chondrocyte formation.
Discussion
Inflammation and syndesmophyte formation are two
defining hallmarks in AS. However, the relationships
between these features, as well as the underlying con-
trolling factors, are poorly understood. Key questions
that remain to be answered are whether the enthesis is
the site of disease initiation, whether inflammation is
necessary for radiographic disease progression, and what
is the nature of the pathological osseous tissue laid down.
By detailed analysis of disease progression in the PGISp
mouse model of AS, we have provided insights into these
questions. Specifically we have demonstrated that osteo-
proliferation is seen only at sites where inflammation pre-
viously occurred, strongly suggesting that inflammation
and IVD destruction are required for disease progression
to bone formation.
The detailed histology analysis in the present study re-
vealed that the inflammatory invasion started at the per-
iphery of the AF. Association of inflammation with the
AF has been previously noted in this model but was not
identified as the inflammation initiating point within
spine [7, 8]. Spinal enthesitis presenting as pannus for-
mation outside of the AF was also reported in HLA-B27
transgenic rats [14] and curdlan-treated SKG mice [15].
We also showed that inflammatory infiltrate and ectopic
chondroproliferation expanded along the adjacent verte-
brae cortical bone surfaces. Although we do not show
definitive proof of entheses in these regions, it is well
established that the longitudinal spinal ligaments have
frequent attachment points in this area [16, 17].
The limited effects of anti-TNF therapies on radio-
graphic progression raised the question as to whether in-
flammation is required for osteoproliferation in AS. Our
detailed histological examination suggests inflammation,
excessive tissue formation and ectopic chondrocyte for-
mation typify early, intermediate and late disease stages,
respectively. We demonstrated that early mesenchymal
expansion initiated before resolution of inflammation.
Although averaging of histological scores suggests over-
lap between the disease stages, examination of individual
vertebrae showed that severe inflammation was never
found simultaneously with severe excessive tissue forma-
tion within the same joint, supporting sequential rather
than parallel progression of these disease features. There-
fore, our model predicts that inflammatory lesions are
likely to have decreased, if not resolved, in the later disease
stages typified by syndesmophyte formation. This predic-
tion is supported by MRI studies in AS patients that have
shown that (1) new syndesmophytes are seen more fre-
quently in vertebral corners with resolved inflammation
[18] and (2) 68 % of syndesmophytes developed from
vertebral corners without active inflammation during
the 2-year observation period [19]. However, some con-
sideration needs to be given to the sensitivity limits of
MRI for detecting mild inflammation [20].
Excessive tissue formation occurred only at vertebral
joints in which the IVD itself had been destroyed, imply-
ing that disease initiates with inflammation which leads
to disc destruction. As inflammation decreases, excessive
tissue formation commences with ectopic chondrocyte
formation occurring late. Such a progression concurs with
the “TNF-brake hypothesis” proposed by Maksymowych
et al. [18], who suggest that a high level of inflammatory
TNF actually inhibits osteoproliferation and this inhibition
is eased as TNF levels drop with resolution of inflamma-
tion. This also matches data from rheumatoid arthritis
models in which osteoblast function is inhibited in the
presence of inflammation [21] and induced after inflam-
mation resolution [22]. However, we also see elevated
TNF expression in the spines of the PGISp mice from in-
flammation throughout the excess tissue production
phases, suggesting that TNF may play a role in the osteo-
proliferation as well as inflammation. Alternatively, these
elevated levels might also reflect the disease heterogeneity
within individual vertebrae and local TNF levels may re-
sult in site-specific impacts on osteoblast regulation.
Enthesitis and osteoproliferation have also been re-
ported in DBA/1 mice [23], HLA-B27/hβ2m transgenic
rats [24] and curdlan-treated SKG mice [15]. However,
the relationship between the processes is not well de-
fined. In the DBA/1 mouse model of ankylosing enthesi-
tis, chondrocyte proliferation was the leading cause of
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ankle ankylosis [23, 25]. The entheseal proliferation and
inflammatory infiltrate were minor in this model, and
treatment with glucocorticoids [26], but not etanercept
[27], did ameliorate inflammation but had no effect on
the ankylosis. In a longitudinal study in HLA-B27/hβ2m
transgenic rats, osteoproliferation was found external to
the joint space separate to inflammatory infiltrates [24]
but was present simultaneously, suggesting distinct but
parallel processes. Interestingly, although blocking TNF
signalling before or after onset prevented or reduced
arthritis, respectively [28], chondroproliferation and
its activation of relevant bone morphogenetic protein
Fig. 5 Early, intermediate and late phases of disease progression are delineated by inflammation, excessive tissue and ectopic chondrocyte formation.
a Unsupervised clustering differentiates the model into three stages corresponding with disease duration. The x-axis depicts the time points of the
mice. The left box (stage 1), middle box (stage 2) and right box (stage 3) represent early, intermediate and late stages of disease development,
respectively. Scores for (b) inflammation, (c) excessive tissue formation and (d) ectopic chondrocyte formation are distinct between these
three groups. e Axial disease was initially characterised by transient inflammation that included vertebral joint infiltration by monocular cells,
activation of tissue remodelling (matrix metalloproteinases, or MMPs) and pro-arthritic inflammatory pathways (tumour necrosis factor, or TNF).
Vertebral joint inflammation culminated in destructive changes, including destruction of the intervertebral disc, the latter of which was irreparable and
would have considerable impact on joint biomechanics. In advanced disease, inflammation is decreased; however, excessive tissue and ectopic
chondrocyte formation driven by chondroidal ossification was the predominant feature and occurred only in joints in which the IVD had been
severely compromised
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signalling were prevented only by early treatment. In the
SKG mouse model, bone formation and erosion were
shown to be adjacent to inflammation, although pro-
gressive association of these different features is unclear
as a detailed longitudinal study was not undertaken [15].
So although evidence from other animal models is am-
biguous, our extensive analysis in the PGISp model clearly
supports a direct progression from inflammation to
cartilage-bone formation.
Direct connection of the ectopic chondrocytes and car-
tilage to the vertebral end plate or growth plate cartilage
was not a consistent histological feature in our model,
indicating that these ectopic tissues were not due to ex-
pansion of existing cartilage structures. The AF [29],
periosteum [30] and ligament [16] all contain potential
chondrocyte progenitors. Therefore, it is possible the
chondrogenesis is initiated using progenitors located
within these disease-affected tissues without direct in-
volvement of pre-existing cartilage. Several features of
the excessive tissue in the advanced disease, such as
cartilage formation and chondrocyte hypertrophy, resem-
bled endochondral ossification. Hypertrophic chondro-
cytes have been shown to be able to transform directly
into osteoblasts and osteocytes [31]. Bleil et al. recently
demonstrated that zygapophyseal joint ankylosis was caused
by direct transformation from cartilage to bone without
chondrocyte hypertrophy [32]. The direct transformation/
ossification from chondrocytes represents chondroidal os-
sification [2, 32] and might be the primary mechanism of
excessive tissue formation in the PGISp model. Examples
of mature syndesmophytes were rare in this study but
more evident in later disease stages. This finding suggests
that the transformation of cartilage to bone in PGISp mice
is a slow process modelling the prolonged window be-
tween disease onset and radiographic change in patients
with AS [33].
Our results suggest that if inflammation is not treated
early enough to prevent irreparable structural damage,
further osteoproliferation at that location will progress
even if the inflammatory process is resolved/attenuated.
The benefits of early intervention regarding both spon-
dylitis and radiographic progression have been demon-
strated with different treatments. After treatment with
infliximab for 16 weeks, 61 % of patients with short disease
duration (13.4 months) had 40 % improvement from base-
line [34] whereas only 47 % of patients with long disease
duration (7.7 years) reached the same criteria after 24 weeks
of treatment [35]. Delaying TNF intervention therapy for
10 years was related to faster radiographic progression
compared with those who started treatment within 10 years
of disease onset [36]. The benefit of early intervention was
also seen using NSAIDs. AS patients with short disease
duration (<5 years) had less radiographic progression [37]
compared with those with long disease duration (11.9 years)
[38] following chronic high-dose NSAID treatment.
These studies suggest that anti-inflammatory therapies
exert better clinical outcomes in patients with early AS/
spondyloarthritis compared with those whose disease is
established.
Conclusions
In summary, our study indicates inflammation leads to
IVD destruction in the PGISp mouse AS model. The latter
is a prerequisite for induction of excessive tissue forma-
tion, and chondroidal ossification rather than endochon-
dral or intramembranous ossification appears to be the
most likely mechanism. Extrapolation of these findings
to human disease suggests that early intervention with
potent anti-inflammatory therapeutic regimens may pre-
vent inflammation-induced destructive changes and conse-
quently reduce the frequency of osteoproliferative events
and joint fusion.
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